[go: up one dir, main page]

UY31273A1 - Fenilendiaminas sustituidas como inhibidores de la interaccion entre mdm2 y p53 - Google Patents

Fenilendiaminas sustituidas como inhibidores de la interaccion entre mdm2 y p53

Info

Publication number
UY31273A1
UY31273A1 UY31273A UY31273A UY31273A1 UY 31273 A1 UY31273 A1 UY 31273A1 UY 31273 A UY31273 A UY 31273A UY 31273 A UY31273 A UY 31273A UY 31273 A1 UY31273 A1 UY 31273A1
Authority
UY
Uruguay
Prior art keywords
mdm2
interaction
phenilendiamins
inhibitors
replaced
Prior art date
Application number
UY31273A
Other languages
English (en)
Inventor
Leys Carina
Poncelet Virginie Sophie
Storck Pierre-Henri
Schoentjes Bruno
Poncelet Alain Philippe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of UY31273A1 publication Critical patent/UY31273A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invencion proporciona compuestos de formula (I), su uso como un inhibidor de una interaccion entre p53-MDM2 así como también proporciona composiciones farmacéuticas que comprenden dichos compuestos de formula (I).
UY31273A 2007-08-06 2008-08-06 Fenilendiaminas sustituidas como inhibidores de la interaccion entre mdm2 y p53 UY31273A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07113878 2007-08-06

Publications (1)

Publication Number Publication Date
UY31273A1 true UY31273A1 (es) 2009-03-02

Family

ID=38872012

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31273A UY31273A1 (es) 2007-08-06 2008-08-06 Fenilendiaminas sustituidas como inhibidores de la interaccion entre mdm2 y p53

Country Status (10)

Country Link
US (1) US8853406B2 (es)
EP (1) EP2185541B1 (es)
AR (1) AR067813A1 (es)
CL (1) CL2008002316A1 (es)
ES (1) ES2534899T3 (es)
PA (1) PA8792401A1 (es)
PE (1) PE20090512A1 (es)
TW (1) TW200922557A (es)
UY (1) UY31273A1 (es)
WO (1) WO2009019274A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2704B1 (en) 2007-09-21 2013-03-03 جانسين فارماسوتيكا ان في Interference inhibition factors between MD2 and B53
NZ594186A (en) 2009-02-04 2012-12-21 Janssen Pharmaceutica Nv Indole derivatives as anticancer agents
US9719970B2 (en) 2012-11-30 2017-08-01 Waters Technologies Corporation Methods and apparatus for the analysis of vitamin D metabolites
TW201429969A (zh) 2012-12-20 2014-08-01 Merck Sharp & Dohme 作爲ｈｄｍ２抑制劑之經取代咪唑吡啶
ES2790419T3 (es) 2013-01-15 2020-10-27 Incyte Holdings Corp Los compuestos de tiazolcarboxamidas y piridinacarboxamida útiles como inhibidores de quinasa de PIM
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
JP2019522633A (ja) 2016-05-20 2019-08-15 ジェネンテック， インコーポレイテッド Ｐｒｏｔａｃ抗体コンジュゲート及び使用方法
JP6957620B2 (ja) 2016-12-01 2021-11-02 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． エストロゲン受容体分解物質としてのテトラヒドロナフタレン誘導体およびテトラヒドロイソキノリン誘導体
MX2022002415A (es) 2019-08-26 2022-03-22 Arvinas Operations Inc Metodos de tratamiento del cancer de mama con derivados de tetrahidronaftaleno como degradadores del receptor de estrogenos.
US12162859B2 (en) * 2020-09-14 2024-12-10 Arvinas Operations, Inc. Crystalline and amorphous forms of a compound for the targeted degradation of estrogen receptor
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO863197A0 (en) 1997-08-18 1997-09-11 Fujisawa Pharmaceutical Co., Ltd. Novel derivatives
US6309492B1 (en) 1998-09-16 2001-10-30 Marc A. Seidner Polymer fill coating for laminate or composite wood products and method of making same
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
BR9915940A (pt) 1998-12-02 2001-09-11 Pfizer Prod Inc Métodos e composições para restaurar a estabilidade conformacional de uma proteìna da famìlia p53
AU1734401A (en) 1999-12-09 2001-06-18 Mitsubishi Pharma Corporation Carboxyamido derivatives
HUP0301094A2 (hu) 2000-09-15 2003-09-29 Anormed Inc. Kemonikinreceptorhoz kötżdż heterociklusos vegyületek, e vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk
DK1379239T3 (da) 2001-03-29 2008-01-07 Lilly Co Eli N(2-aryl-ethyl)-benzyl-aminer som antagonister af 5 HT6 receptoren
US20030149038A1 (en) 2001-11-09 2003-08-07 The Regents Of The University Of California Alpha-helix mimicry by a class of organic molecules
IL161692A0 (en) 2001-11-13 2004-09-27 Dimensional Pharm Inc 14-benzodiazepine derivatives and pharmaceutical compositions containing the same
RU2305095C2 (ru) 2001-12-18 2007-08-27 Ф.Хоффманн-Ля Рош Аг Цис-2,4,5-трифенилимидазолины и фармацевтическая композиция на их основе
GB0215650D0 (en) 2002-07-05 2002-08-14 Cyclacel Ltd Bisarylsufonamide compounds
ES2349358T3 (es) 2004-09-22 2010-12-30 Janssen Pharmaceutica Nv Inhibidores de la interacción entre mdm2 y p53.

Also Published As

Publication number Publication date
US8853406B2 (en) 2014-10-07
WO2009019274A1 (en) 2009-02-12
TW200922557A (en) 2009-06-01
PE20090512A1 (es) 2009-04-29
AR067813A1 (es) 2009-10-21
US20110130418A1 (en) 2011-06-02
ES2534899T3 (es) 2015-04-30
CL2008002316A1 (es) 2009-07-17
EP2185541B1 (en) 2015-01-28
PA8792401A1 (es) 2009-03-31
EP2185541A1 (en) 2010-05-19

Similar Documents

Publication Publication Date Title
UY31273A1 (es) Fenilendiaminas sustituidas como inhibidores de la interaccion entre mdm2 y p53
ECSP077335A (es) Inhibidores de la interaccion entre mdm2 y p53
ECSP10010722A (es) Compuestos orgánicos
CR11427A (es) 2-fluoro-2 - desoxitetrahidrouridinas como inhibidores de citidina desaminasa
EA201070278A1 (ru) Ингибиторы гамма-секретазы
CR9786A (es) Compuestos de bencimidazol-tiofeno
GT200900027A (es) Compuestos organicos
CR20110028A (es) Derivados de pirimidina como inhibidores de cinasa
NO20084334L (no) Farmasoytiske sammensetninger
CU20070160A7 (es) Pirrolopirazoles, inhibidores potentes de quinasa
EA200971051A1 (ru) Ингибиторы p70 s6 киназы
DK2134691T3 (da) Quinolinonderivativer som parp- og tank-inhibitorer
UY31349A1 (es) Inhibidores de la interaccion entre mdm2 y p53
CR11618A (es) Inhibidores macrocíclicos de serina proteasa
NI200900040A (es) Derivados de quinazolinona 5-substituidos como agentes antitumorales.
UY30748A1 (es) Compuesto0s novedosos
CL2008002539A1 (es) Compuestos derivados de indol sustituidos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion viral
CL2011002857A1 (es) Compuestos derivados de fenil o heteroaril piridina, inhibidores de sintasa de aldosterona; composicion farmaceutica que comprende un compuesto; combinacion farmaceutica que comprende un compuesto; y uso de los compuestos en el tratamiento de enfermedades cardiovasculares.
CL2012003104A1 (es) Compuestos derivados de multiheteroarilos, inhibidores de prostaglandina d sintasa hematopoyetica (h-pgds); y composicion farmaceutica que los comprende.
HN2007000437A (es) Compuestos de pirazolina y su uso y composiciones farmaceuticas
HN2009000566A (es) Nuevos derivados de diosmetina, su procedimiento de prearacion y las composiciones farmaceuticas que lo contienen.
EA201270590A1 (ru) Ингибиторы акт
EA201170680A1 (ru) Ингибиторы акт и p70 s6-киназы
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
PA8667201A1 (es) Nuevos compuestos farmaceuticos